Author:
Ruan Ruiwen,Li Li,Li Xuan,Huang Chunye,Zhang Zhanmin,Zhong Hongguang,Zeng Shaocheng,Shi Qianqian,Xia Yang,Zeng Qinru,Wen Qin,Chen Jingyi,Dai Xiaofeng,Xiong Jianping,Xiang Xiaojun,Lei Wan,Deng Jun
Abstract
Abstract
Background
Fibroblast growth factors (FGFs) and their receptors (FGFRs) play a crucial role in cell fate and angiogenesis, with dysregulation of the signaling axis driving tumorigenesis. Therefore, many studies have targeted FGF/FGFR signaling for cancer therapy and several FGFR inhibitors have promising results in different tumors but treatment efficiency may still be improved. The clinical use of immune checkpoint blockade (ICB) has resulted in sustained remission for patients.
Main
Although there is limited data linking FGFR inhibitors and immunotherapy, preclinical research suggest that FGF/FGFR signaling is involved in regulating the tumor microenvironment (TME) including immune cells, vasculogenesis, and epithelial-mesenchymal transition (EMT). This raises the possibility that ICB in combination with FGFR-tyrosine kinase inhibitors (FGFR-TKIs) may be feasible for treatment option for patients with dysregulated FGF/FGFR signaling.
Conclusion
Here, we review the role of FGF/FGFR signaling in TME regulation and the potential mechanisms of FGFR-TKI in combination with ICB. In addition, we review clinical data surrounding ICB alone or in combination with FGFR-TKI for the treatment of FGFR-dysregulated tumors, highlighting that FGFR inhibitors may sensitize the response to ICB by impacting various stages of the “cancer-immune cycle”.
Funder
Natural Science Foundation of Jiangxi Province
Government of Jiangxi Province
Jiangxi Provincial Department of Science and Technology
Foundation of Jiangxi Educational Commission
National Natural Science Foundation of China
Youth Science Foundation of Jiangxi Province
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Medicine
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献